Query the FDA Orange Book patent index for expirations landing in 2026–2030, and one number jumps out immediately: two applications alone — NDA 022272 (OxyContin) and NDA 206627 (Hysingla ER), both extended-release opioids from Purdue Pharma — each carry 98 separate patents expiring in the single year 2027, more than any other application in the dataset. Across the full index of 21,849 patent-listing records, 2027 is the single busiest expiration year in the near term, with 2,157 individual patent listings lapsing, versus 1,613 in 2026, 1,274 in 2028, 1,597 in 2029, and 1,705 in 2030.
That 2027 spike is not one blockbuster losing protection — it is a small number of applications each defended by dozens of patents expiring in the same year, a pattern regulators call a patent thicket. Companies extend a drug's effective monopoly well past its core 20-year patent term by layering on formulation patents, device patents, and method-of-use patents for each new delivery mechanism (capsule vs. tablet, once-daily vs. twice-daily, abuse-deterrent coatings). Each new patent restarts a potential 30-month litigation stay against a generic challenger under Hatch-Waxman, so a thicket does not need any single patent to be strong — it only needs enough of them to make litigation expensive and slow for a would-be generic entrant.
Patent expiration is only half the clock
The Orange Book exclusivity index (2,195 records) tells a related but distinct story. Regulatory exclusivity — New Chemical Entity (NCE), pediatric (PED), new patient population (NPP), orphan drug (ODE) — runs on its own statutory clock, independent of patents, and cannot be litigated away. Of exclusivity periods ending in the same 2026–2030 window, NCE exclusivity is the largest single category (368 of 1,904 near-term records), followed by pediatric extensions (252) and new-patient-population exclusivity (143). A generic cannot launch until both the last-standing patent and the last-standing exclusivity period have cleared — whichever is later controls the actual launch date.
What this means for generic-entry timing
For most of the 2,157 patents expiring in 2027, regulatory exclusivity has already run out by then — the field narrows to patent litigation alone. That is exactly the dynamic the FTC has targeted: in 2023 and again in 2025 the agency challenged more than 200 Orange Book patent listings it says were improperly filed on device or formulation components specifically to trigger 30-month stays against generics, an enforcement thesis built on the same thicket mechanics visible in this dataset. Applications defended by 90+ patents in a single expiration year are the clearest candidates for that kind of scrutiny.
Caveats
This index tracks listed patent and exclusivity dates as published, not litigation outcomes, settlements, or authorized-generic deals, any of which can move a real launch date years earlier or later than the raw expiration date implies. It also has no drug-name field — matching appl_no to brand names required cross-referencing FDA approval letters separately, and a handful of app numbers could not be resolved. Finally, "expires" in the raw Orange Book data includes patents already delisted or disclaimed in later filings that this snapshot does not distinguish, so cliff-year counts are an upper bound, not a launch forecast.
Why this matters: as more once-daily and abuse-deterrent reformulations from the 2010s reach their filed patent limits, 2027 is shaping up as a concentrated test of whether thicket-style Orange Book listings still function as a generic-delay tool or whether post-2023 FTC pressure has started to erode that strategy in practice.